Immune checkpoint blockade is regarded as a promising therapy for numerous solid tumors, including melanoma and non-small cell lung cancer.8,9 Immune checkpoint inhibitors that target PD-1 or PD-L1 also have been tested in CRC.8 However, only a limited number of patients have demonstrated a response to anti-PD-1 or anti-PD-L1 immunotherapy in recent clinical trials.8 The gene discussed is CD274; the disease is non-small cell lung carcinoma.